Adam Cohen
Hoogleraar Klinische Farmacologie
- Naam
- Prof.dr. A.F. Cohen
- Telefoon
- +31 71 526 9111
- ac@chdr.nl
- ORCID iD
- null
Adam Cohen is hoogleraar klinische farmacologie en was tot begin 2018 de algemeen bestuurder van het Centre for Human Drug Research (www.chdr.nl). CHDR is een toonaangevend instituut dat in samenwerking met het LUMC en de Universiteit Leiden nieuwe geneesmiddelen onderzoekt bij de mens.
Meer informatie over Adam Cohen
Adam Cohen is hoogleraar klinische farmacologie en was tot begin 2018 de algemeen bestuurder van het Centre for Human Drug Research (CHDR). CHDR is een toonaangevend instituut dat in samenwerking met het LUMC en de Universiteit Leiden nieuwe geneesmiddelen onderzoekt bij de mens
Hij is gastmedewerker bij de afdeling Nierziekten van het LUMC. Hij is tevens hoofdredacteur van het British Journal of Clinical Pharmacology. Als een van de eerste vice voorzitters van de CCMO is hij betrokken geweest bij de formatie van het huidige beleid voor de regulering van geneesmiddelonderzoek tussen 1999 en 2011. Hij is verder lid van de Raad van Toezicht van het Oogziekenhuis Rotterdam, de wetenschappelijke adviesraad van het Duitse Instituut voor Lucht en Ruimtevaart onderzoek en actief in meerdere internationale commissies. Hij is bestuurder van de Stichting Leidse Hofjesconcerten. In 2017 kreeg hij de Lilly Prize van de British Pharmacological Society.
Klinische farmacologie
Klinisch farmacologen bestuderen de werking van geneesmiddelen bij de mens. Alle artsen gebruiken geneesmiddelen bij hun behandelingen, of ze nu voornamelijk chirurgisch of anderszins werkzaam zijn dus die kennis is in de hele geneeskunde van belang. CHDR is betrokken bij onderzoek naar geneesmiddelen voor bijna alle ziektes. Het wordt van toenemend belang dat er niet alleen nieuwe geneesmiddelen komen maar ook betere methodes om te zien of die middelen werken. Deze twee aspecten zijn leidend in het onderzoek. Een belangrijk aspect van het onderzoek is de komende jaren de evaluatie van effecten van geneesmiddelen in de thuissituatie, waarbij gebruik gemaakt wordt van geavanceerde electronica en aangepaste zogenaamde wearables. Misschien nog belangrijker is het onderwijs aan artsen tijdens en na hun opleiding over hoe geneesmiddelen werken en deze in aanleg gevaarlijke middelen veilig gebruikt moeten worden om mensen beter te maken.
Academische carrière
Adam Cohen heeft farmacie en geneeskunde gestudeerd in Leiden en heeft daarna in Londen gewerkt bij de afdeling klinische farmacologie van de Wellcome Research Laboratories en de afdeling interne geneeskunde van King’s College. Hij is in Leiden gepromoveerd op 29 mei 1986 bij Professor Douwe Breimer. Na terugkeer in Nederland in 1987 is hij benoemd als algemeen directeur van de Stichting Centre for Human Drug Research waarvan hij de ontwikkeling heeft geleid tot 2018. De organisatie had toen een omvang van 300 mensen. Op 31 maart 1995 hield hij zijn oratie als hoogleraar klinische farmacologie en hij zal die positie bekleden tot 9 november 2018
Vanaf 1-1 2018 is hij bij CHDR directeur van de afdeling Innovation Services (InnoS) en houd zich bezig met advisering over geneesmiddelontwikkeling en innovatieve producten voor de evaluatie van geneesmiddeleffecten. Hij is een van de oprichters van het Paul Janssen FutureLab in Leiden, een opleidingsinstituut voor onderzoekers die interventies in de gezondheidszorg willen ontwikkelen.
Hoogleraar Klinische Farmacologie
- Faculteit Geneeskunde
- Divisie 2
- Interne Geneeskunde
- Nierziekten
Hoogleraar Klinische farmacologie
- Wiskunde en Natuurwetenschappen
- Leiden Academic Centre for Drug Research
- LACDR/Algemeen
Contact
- Beek, C. van der & Cohen, A. F. (2023), Klinisch geneesmiddelenonderzoek, Nederlands Tijdschrift voor Geneeskunde 167.
- Wall H.E.C. van der, Hassing G.J., Doll R.J., Westen G.J.P. van, Cohen A.F., Selder J.L., Kemme M., Burggraaf J. & Gal P. (2022), Cardiac age detected by machine learning applied to the surface ECG of healthy subjects: creation of a benchmark, Journal of Electrocardiology 72: 49-55.
- Wall H.E.C. van der Doll R.J., Westen G.J.P. van, Niemeyer-van der Kolk T., Feiss G., Pinckaers H., Doorn M.B.A. van, Nijsten T., Sanders M.G.H., Cohen A.F., Burggraaf J., Rissmann R. & Pardo L.M. (2022), Discriminative machine learning analysis for skin microbiome: observing biomarkers in patients with seborrheic dermatitis, Journal of Artificial Intelligence for Medical Sciences 3(1-2): 1-7.
- Wall, H.E.C. van der; Hassing, G.J.; Doll, R.J.; Westen, G.J.P. van; Cohen, A.F.; Selder, J.L.; Kemme, M.; Burggraaf, J. & Gal, P. (2022), Cardiac age detected by machine learning applied to the surface ECG of healthy subjects, Journal of Electrocardiology 72: 49-55.
- Wall H.E.C. van der, Doll R.J., Westen G.J.P. van, Koopmans I., Zuiker R.G., Burggraaf J. & Cohen A.F. (2021), Using machine learning techniques to characterize sleep-deprived driving behavior, Traffic Injury Prevention 22(5): 366-371.
- Rijsbergen M., Niemeyer-van der Kolk T., Rijneveld R., Pinckaers J.H.F.M., Meshcheriakov I., Bavinck J.N.B., Doorn M.B.A. van, Hogendoorn G., Feiss G., Cohen A.F., Burggraaf J., Poelgeest M.I.E. van & Rissmann R. (2020), Mobile e-diary application facilitates the monitoring of patient-reported outcomes and a high treatment adherence for clinical trials in dermatology, Journal of the European Academy of Dermatology and Venereology 34(3): 633-639.
- Wall H.E.C. van der, Doll R.J., Westen G.J.P. van der, Koopmans I., Zuiker R.G., Burggraaf J. & Cohen A.F. (2020), The use of machine learning improves the assessment of drug-induced driving behaviour, Accident Analysis & Prevention 148: 105822.
- Meer L. van, Moerland M., Gallagher J., Doorn M.B.A. van, Prens E.P., Cohen A.F., Rissmann R. & Burggraaf J. (2017), Injection site reactions after subcutaneous oligonucleotide therapy, British Journal of Clinical Pharmacology 82(2): 340-351.
- Goulooze S.C., Franson K.L., Cohen A.F. & Rissmann R. (2017), Clinical Pharmacology Research Internships at the Interface between Academia and Industry: Students' Perceptions and Scientific Output, Basic & Clinical Pharmacology & Toxicology 121(1): 22-28.
- Kanhai K.M.S., Goulooze S.C., Stevens J., Hay J.L., Dent G., Verma A., Hankemeier T., Boer T. de, Meijering H., Chavez J.C., Cohen A.F. & Groeneveld G.J. (2016), Quantifying Beta‐Galactosylceramide Kinetics in Cerebrospinal Fluid of Healthy Subjects Using Deuterium Labeling, Clinical and Translational Science 9(6): 321-327.
- Goulooze S.C., Cohen A.F. & Rissmann R. (2016), Olaparib, British Journal of Clinical Pharmacology 81(1): 171-173.
- Goulooze S.C., Cohen A.F. & Rissmann R. (2015), Bedaquiline, British Journal of Clinical Pharmacology 80(2): 182-184.
- Goulooze S.C., Cohen A.F. & Rissmann R. (2015), Mirabegron, British Journal of Clinical Pharmacology 80(4): 762-764.
- Goulooze S.C., Cohen A.F. & Rissmann R. (2015), Lomitapide, British Journal of Clinical Pharmacology 80(2): 179-181.
- Westra, A.E.; Sukhai, R.N.; Wit, J.M.; Beaufort, I.D. de & Cohen, A.F. (2010), Acceptable risks and burdens for children in research without direct benefit: a systematic analysis of the decisions made by the Dutch Central Committee, Journal of Medical Ethics 36(7): 420-424.
- Miley G.K., Carilli C.L., Taylor E.N., De Breuck C. & Cohen A.F. (2009), High Redshift Radio Galaxies: Laboratories for Massive Galaxy and Cluster Formation in the early Universe. [overig].
- Zuurman L., Roy C., Schoemaker R.C., Hazekamp A., Den Hartigh J., Bender J.C.M.E., Verpoorte R., Pinquier J., Cohen A.F. & Gerven J.M.A. van (2008), Effect of intrapulmonary tetrahydrocannabinol administration in humans, Journal of Psychopharmacology 22: 707-716.
- Jacobs G.E. & Cohen A.F. (2008), The South London and Maudsley NHS Foundation Trust and Oxleas NHS Foundation Trust Prescribing Guidelines, 9th edition, British Journal of Clinical Pharmacology : .
- Strougo A, Zuurman L, Roy C, Pinquier JL, van Gerven JMA, Cohen AF & Schoemaker RC (2008), Modelling of the concentration-effect relationship of THC on central nervous system parameters and heart rate - insight into its mechanisms of action and a tool for clinical research and development of cannabinoids, Journal of Psychopharmacology 22(7).
- Broeyer FJF, Osanto S, van Eck HJR, van Steijn AQMJ, Ballieux BEPB, Schoemaker RC, Cohen AF & Burggraaf J (2008), Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy, Journal of Cancer Research and Clinical Oncology 134(9).
- Zoethout RWM, van Gerven JMA, Dumont GJH, Paltansing S, van Burgel ND, van der Linden M, Dahan A, Cohen AF & Schoemaker RC (2008), A comparative study of two methods for attaining constant alcohol levels, British Journal of Clinical Pharmacology 66(5).
- Zuurman L, Roy C, Schoemaker RC, Hazekamp A, den Hartigh J, Bender JCME, Verpoorte R, Pinquier JL, Cohen AF & van Gerven JMA (2008), Effect of intrapulmonary tetrahydrocannabinol administration in humans, Journal of Psychopharmacology 22(7).
- Liem-Moolenaar M, De Boer P, Zoethout RWM, Franson K, Cohen AF & Van Gerven JMA (2008), Study investigating R231857 effects on scopolamine-induced CNS impairment in healthy men, European Neuropsychopharmacology 18.
- Broeyer FJF, van Aken BE, Suzuki J, Kemme MJB, Schoemaker HC, Cohen AF, Mizushima Y & Burggraaf J (2008), The pharmacokinetics and effects of a long-acting preparation of superoxide dismutase (PC-SOD) in man, British Journal of Clinical Pharmacology 65(1).
- de Haas SL, de Visser SJ, van der Post JP, Schoemaker RC, van Dyck K, Murphy MG, de Smet M, Vessey LK, Ramakrishnan R, Xue L, Cohen AF & van Gerven JMA (2008), Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha(2,3) subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers, Journal of Psychopharmacology 22(1).
- Boot J.D., Haas S. de, Tarasevych S., Roy C., Wang L., Amin D., Cohen J., Sterk P.J., Miller B., Paccaly A., Burggraaf J., Cohen A.F. & Diamant Z. (2007), Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma, American Journal of Respiratory and Critical Care Medicine 175(5): 450-457.
- Doorn M. van, Vogels J., Tas A., Hoogdalem E.J. van, Burggraaf J., Cohen A.F. & Greef J. van der (2007), Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers, British Journal of Clinical Pharmacology 63(5): 562-574.
- Liem-Moolenaar M., Dunn M., Visser S.J. de, Schoemaker R.C., Cohen A.F., Bye A., Lowy M., Gray F. & Gerven J.M.A. van (2007), Psychomotor and cognitive effects of a single dose of SB223412 in healthy volunteers compared to placebo or haloperidol, Basic & Clinical Pharmacology & Toxicology 101(Suppl 1): 106.
- Zuurman L., Passier P.C., Kam M. de, Kleijn H.J., Cohen A.F. & Gerven J.M.A. van (2007), Pharmacokinetic and pharmacodynamic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers, Clinical Pharmacology & Therapeutics 81(S12): .
- zoethout R.W.M., Haas S.L. de, Duck K. van, Semt M. de, Rosen L.B., Murphy M.G., Gottesdiener K.M., Schoemaker R.C., Cohen A.F. & Gerven J.M.A. van (2007), A double-blind, double-dummy, randomized, placebo-controlled, crossover study to investigate the effects of ethanol and TPA023 on essential tremor, Basic & Clinical Pharmacology & Toxicology 101(Suppl 1): 91-92.
- Zuurman L., Roy C., Asset G., Amatsaleh A., Guimaraes L., Pinquier J., Cohen A.F. & Gerven J.M.A. van (2007), The effects of the novel CB1 antagonist AVE1625 on the THC-induced changes on central nervous system effects and heart rate, Clinical Pharmacology & Therapeutics 81(suppl 1:S4): .
- Haas S.L. de, Visser S.J. de, Kam M.L. de, Smet M. de, Murphy G., Vessey L., Cohen A.F. & Gerven J.M.A. van (2007), The selective central nervous system (CNS) effects of two different GABA-A Alpha 2,3 subtype selective agonists compared to lorazepam, Clinical Pharmacology & Therapeutics 81(S63): .
- Bronswijk H. van, Dubois E.A., Zitman F.G. & Cohen A.F. (2007), New drugs; varenicline, Nederlands Tijdschrift voor Geneeskunde 151: 2503-2504.
- Haas S.L. de, Visser S.J. de, Post J.P. van der, Smet M. de, Schoemaker R.C., Rijnbeek B., Cohen A.F., Vega J.M., Agrawal N.G.B., Goel T.V., Simpson R.C., Pearson L.K., Li S., Hesney M., Murphy M.G. & Gerven J.M.A. van (2007), Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA a2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers, Journal of Psychopharmacology 21: 374-383.
- Haas S. de, Otte A., Weerd A. de, Erp G. van, Cohen A.F. & Gerven J.M.A. van (2007), Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy, Journal of clinical sleep medicine 3: 473-478.
- Haas S. de, Dingemanse J., Hoever P., Cohen A.F. & Gerven J.M.A. van (2007), Pseudo-hallucinations after zolpidem intake: A case report, 27: 728-730.
- Boot JD, de Haas S, Tarasevych S, Roy C, Wang L, Amin D, Cohen J, Sterk PJ, Miller B, Paccaly A, Burggraaf J, Cohen AF & Diamant Z (2007), Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma, American Journal of Respiratory and Critical Care Medicine 175(5).
- van der Vorst MMJ, Holthe JEKV, den Hartigh J, van der Heijden AJ, Cohen AF & Burggraaf J (2007), Absence of tolerance and toxicity to high-dose continuous intravenous furosemide in haemodynamically unstable infants after cardiac surgery, British Journal of Clinical Pharmacology 64(6).
- de Haas S, Dingemanse J, Hoever P, Cohen A & van Gerven J (2007), Pseudohallucinations after Zolpidem intake - A case report, Journal of Clinical Psychopharmacology 27(6).
- de Hass SL, de Visser SJ, van der Post JP, de Smet M, Schoemaker RC, Rijnbeek B, Cohen AF, Vega JM, Agrawal NGB, Goel TV, Simpson RC, Pearson LK, Li S, Hesney M, Murphy MG & van Gerven JMA (2007), Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A)alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers, Journal of Psychopharmacology 21(4).
- Boots I, Sukhai RN, Klein RH, Holl RA, Wit JM, Cohen AF & Burggraaf J (2007), Stimulation programs for pediatric drug research - do children really benefit?, European Journal of Pediatrics 166(8).
- Cohen A, Rovelli A, Merlo DF, van Lint MT, Lanino E, Bresters D, Ceppi M, Bocchini V, Tichelli A & Socie G (2007), Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: An EBMT late effects working party study, Journal of Clinical Oncology 25(17).
- Zuurman L, Roy C, Schoemaker RC, Asset G, Amatsaleh A, Guimaraes L, Pinquier JL, Cohen AF & van Gerven JMA (2007), Inhibition of THC-induced effects on central nervous system effects and heart rate by a novel CB1 receptor antagonist AVE1625, British Journal of Clinical Pharmacology 63(6).
- de Haas SL, de Visser SJ, de Kam ML, de Smet M, Murphy G, Vessey L, Cohen AF & van Gerven JM (2007), The selective central nervous system (CNS) effects of two different GABA(A) alpha(2, 3) subtype-selective agonists compared to lorazepam., Clinical Pharmacology and Therapeutics 81.
- Boot JD, de Haas SL, Tarasevych S, Roy C, Wang L, Amin D, Paccaly AJ, Sterk PJ, Miller B, Burggraaf J, Cohen AF & Diamant Z (2007), Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma., Clinical Pharmacology and Therapeutics 81.
- Zuurman L, Passier PC, de Kam M, Kleijn HJ, Cohen AF & van Gerven JM (2007), Pharmacokinetic and pharmacodynamic effects of the intravenously administered CB1 receptor agonist org 28611 in healthy male volunteers., Clinical Pharmacology and Therapeutics 81.
- Zuurman L, Roy C, Schoemaker RC, Asset G, Amatsaleh A, Guimaraes L, Pinquier J, Cohen AF & van Gerven JM (2007), The effects of the novel CB1 antagonist AVE1625 on THC-induced changes on central nervous system effects and heart rate., Clinical Pharmacology and Therapeutics 81.
- Twiss IM, van den Berk AHM, de Kam ML, Bosch JJ, Cohen AF, Vermeij P & Burggraaf J (2006), A comparison of the gastrointestinal effects of the nitrogen-containing Bisphosphonates pamidronate, alendronate, and olpadronate in humans, Journal of Clinical Pharmacology 46(4).
- van Doorn M, Kemme M, Ouwens M, van Hoogdalem EJ, Jones R, Romijn H, de Kam M, Schoemaker R, Burggraaf K & Cohen A (2006), Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers, British Journal of Clinical Pharmacology 62(4).
- Cohen J., Burggraaf J., Schoemaker R.C., Sterk P.J., Cohen A.F. & Diamant Z. (2005), Relationship between airway responsiveness to neurokinin A and methacholine in asthma, Pulmonary Pharmacology and Therapeutics 17: 171-176.
- Dumont G.J.H., Visser S.J. de, Cohen A.F. & Gerven J.M.A. van (2005), Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects, British Journal of Clinical Pharmacology 59: 495-510.
- Post J.P. van der, Visser S.J. de, Kam M.L. de, Woelfler M., Hilt D.C., Vornov J., Burak E.S., Bortey E., Slusher B.S., Limsakun T., Cohen A.F. & Gerven J.M.A. van (2005), The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693, British Journal of Clinical Pharmacology 60: 128-136.
- Boot J.D., Tarasevych S., Sterk P.J., Schoemaker R.C., Wang L., Amin D., Cohen A.F. & Diamant Z. (2005), Reversal of the late asthmatic response increases exhaled nitric oxide, Respiratory Medicine 99: 1591-1594.
- Dumont G.J.H., Visser S.J. de, Cohen A.F. & Gerven J.M.A. van (2005), Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy volunteers, British Journal of Clinical Pharmacology 59: 495-510.
- van der Post JP, de Visser SJ, de Kam ML, Woelfler M, Hilt DC, Vornov J, Burak ES, Bortey E, Slusher BS, Limsakun T, Cohen AF & van Gerven JMA (2005), The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693, British Journal of Clinical Pharmacology 60(2).
- Dumont GJH, de Visser SJ, Cohen AF & van Gerven JMA (2005), Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects, British Journal of Clinical Pharmacology 59(5).
- Zuurman L, Roy C, Hazekamp A, Schoemaker R, Hartigh JD, Bender JCME, Pinquier JL, Cohen AF & van Gerven JMA (2005), Effect of THC administration in humans: methodology study for further pharmacodynamic studies with cannabinoid agonist or antagonist, British Journal of Clinical Pharmacology 59(5).
- Cohen J, Burggraaf J, Schoemaker RC, Sterk PJ, Cohen AF & Diamant Z (2005), Relationship between airway responsiveness to neurokinin A and methacholine in asthma, Pulmonary Pharmacology and Therapeutics 18(3).
- Kamerling IMC, Van Haarst AD, De Kam ML, Cohen AF, Masclee AAM & Burggraaf J (2004), Gallbladder volume as a biomarker for the motilin effect in healthy volunteers and patients with functional dyspepsia, Alimentary Pharmacology and Therapeutics 19(7).
- Buijs MM, Romijn JA, Burggraaf J, de Kam ML, Frolich M, Ackermans MT, Sauerwein HP, Cohen AF, Meinders AE & Pijl H (2004), Glucose homeostasis in abdominal obesity: hepatic hyperresponsiveness to growth hormone action, AJP - Endocrinology and Metabolism 287(1).
- Kamerling IMC, van Haarst AD, Burggraaf J, Schoemaker RC, de Kam ML, Heinzerling H, Cohen AF & Masclee AAM (2004), Effects of a nonpeptide motilin receptor antagonist on proximal gastric motor function, British Journal of Clinical Pharmacology 57(4).
- van der Post J, de Waal PP, de Kam ML, Cohen AF & van Gerven JMA (2004), No evidence of the usefulness of eye blinking as a marker for central dopaminergic activity, Journal of Psychopharmacology 18(1).
- Gijsman HJ, Cohen AF & van Gerven JMA (2004), The application of the principles of clinical drug development to pharmacological challenge tests of the serotonergic system, Journal of Psychopharmacology 18(1).
- van der Post JP, de Visser SJ, Schoemaker RC, Cohen AF & van Gerven JMA (2004), Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients, Journal of Psychopharmacology 18(2).
- Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A, Korthof E, Weis J, Levy V & Tichelli A (2003), Nonmalignant late effects after allogeneic stem cell transplantation, Blood 101(9).
- Kemme MJB, Post JPV, Schoemaker RC, Straub M, Cohen AF & van Gerven JMA (2003), Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension, British Journal of Clinical Pharmacology 55(6).
- Kamerling IMC, Burggraaf J, van Haarst AD, Oppenhuizen-Duinker MF, Schoemaker HC, Biemond I, Jones R, Heinzerling H, Cohen AF & Masclee AAM (2003), The effect of motilin on the rectum in healthy volunteers, British Journal of Clinical Pharmacology 55(6).
- Rijnbeek B, de Visser SJ, Franson KL, Cohen AF & van Gerven JMA (2003), REM sleep effects as a biomarker for the effects of antidepressants in healthy volunteers, Journal of Psychopharmacology 17(2).
- Buijs MM, Burggraaf J, Wijbrandts C, de Kam ML, Frolich M, Cohen AF, Romijn JA, Sauerwein HP, Meinders AE & Pijl H (2003), Blunted lipolytic response to fasting in abdominally obese women: evidence for involvement of hyposomatotropism, American Journal of Clinical Nutrition 77(3).
- Kamerling IMC, Van Haarst AD, Burggraaf J, Schoemaker RC, Biemond I, Heinzerling H, Jones R, Cohen AF & Masclee AAM (2003), Motilin effects on the proximal stomach in patients with functional dyspepsia and healthy volunteers, AJP - Gastrointestinal and Liver Physiology 284(5).
- Pieters MSM, van Steveninck AF, Schoemaker RC, Kroon JM, van Gerven JMA & Cohen AF (2003), The psychomotor effects of carbamazepine in epileptic patients and healthy volunteers, Journal of Psychopharmacology 17(3).
- Kamerling IMC, van Haarst AD, Burggraaf J, de Kam M, Biemond I, Jones R, Cohen AF & Masclee AAM (2002), Exogenous motilin affects postprandial proximal gastric motor function and visceral sensation, Digestive Diseases and Sciences 47(8).
- Kamerling IMC, Van Haarst AD, Burggraaf J, Schoemaker HC, Biemond I, Jones R, Cohen AF & Masclee AAM (2002), Dose-related effects of motilin on proximal gastrointestinal motility, Alimentary Pharmacology and Therapeutics 16(1).
- Buijs MM, Burggraaf J, Langendonk JG, Schoemaker RC, Frolich M, Arndt JW, Cohen AF, Romijn JA, Ackermans MT, Sauerwein HP, Meinders AE & Pijl H (2002), Hyposomatotropism blunts lipolysis in abdominally obese women, Journal of Clinical Endocrinology and Metabolism 87(8).
- Gijsman HJ, van Gerven JMA, Verkes RJ, Schoemaker RC, Pieters MSM, Pennings EJM, Hessing TJ & Cohen AF (2002), Saccadic peak velocity and EEG as end-points for a serotonergic challenge test, Human Psychopharmacology: Clinical and Experimental 17(2).
- Schoemaker RC, Buijs MM, Pijl H, Burggraaf J & Cohen AF (2002), Modeling the influence of growth hormone on lipolysis, Journal of Pharmacokinetics and Pharmacodynamics 29(2).
- Buijs MM, Romijn JA, Burggraaf J, De Kam ML, Cohen AF, Frolich M, Stellaard F, Meinders AE & Pijl H (2002), Growth hormone blunts protein oxidation and promotes protein turnover to a similar extent in abdominally obese and normal-weight women, Journal of Clinical Endocrinology and Metabolism 87(12).
- van der Post J, Noordzij LAW, de Kam ML, Blauw GJ, Cohen AF & van Gerven JMA (2002), Evaluation of tests of central nervous system performance after hypoxemia for a model for cognitive impairment, Journal of Psychopharmacology 16(4).
- Pijl H, Langendonk JG, Burggraaf J, Frolich M, Cohen AF, Veldhuis JD & Meinders AE (2001), Altered neuroregulation of GH secretion in viscerally obese premenopausal women, Journal of Clinical Endocrinology and Metabolism 86(11).
- Langendonk JG, Veldhuis JD, Burggraaf J, Schoemaker RC, Cohen AF, Meinders AE & Pijl H (2001), Estimation of growth hormone secretion rate: impact of kinetic assumptions intrinsic to the analytical approach, AJP - Regulatory, Integrative and Comparative Physiology 280(1).
- Burggraaf J, Westendorp RGJ, in't Veen JCCM, Schoemaker RC, Sterk PJ, Cohen AF & Blauw GJ (2001), Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients, Thorax 56(7).
- Verkes RJ, Gijsman HJ, Pieters MSM, Schoemaker RC, de Visser S, Kuijpers M, Pennings EJM, de Bruin D, Van de Wijngaart G, Van Gerven JMA & Cohen AF (2001), Cognitive performance and serotonergic function in users of ecstasy, Psychopharmacology 153(2).
- Twiss IM, Burggraaf J, Schoemaker RC, van Elburg RM, den Hartigh J, Cohen AF & Vermeij P (2001), The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: Studies with oral pamidronate, Clinical Pharmacology and Therapeutics 69(6).
- Burggraaf J, Tulen JHM, Lalezari S, Schoemaker RC, De Meyer PHEM, Meinders AE, Cohen AF & Pijl H (2001), Sympathovagal imbalance in hyperthyroidism, AJP - Endocrinology and Metabolism 281(1).
- Pijl H, de Meijer PHEM, Langius J, Coenegracht GIGM, van den Berk AHM, Shaw PKC, Boom H, Schoemaker RC, Cohen AF, Burggraaf J & Meinders AE (2001), Food choice in hyperthyroidism: Potential influence of the autonomic nervous system and brain serotonin precursor availability, Journal of Clinical Endocrinology and Metabolism 86(12).
- Burggraaf J, Lalezari S, Emeis JJ, Vischer UM, de Meyer PHEM, Pijl H & Cohen AF (2001), Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol, Thyroid 11(2).
- Kemme MJB, Burggraaf J, Schoemaker RC, Cohen AF & Blauw GJ (2000), No evidence for functional involvement of 5-HT2B receptors in serotonin-induced vasodilatation in the human forearm, Journal of Cardiovascular Pharmacology 36(6).
- Burggraaf J, Schoemaker RC, Lentjes EGWM & Cohen AF (2000), Sorbitol as a marker for drug-induced decreases of variable duration in liver blood flow in healthy volunteers, European Journal of Pharmaceutical Sciences 12(2).
- de Roode A, van Gerven JMA, Schoemaker RC, Engbers FHM, Olieman W, Kroon JR, Cohen AF & Bovill JG (2000), A comparison of the effects of propofol and midazolam on memory during two levels of sedation by using target-controlled infusion, Anesthesia and Analgesia 91(5).
- Weijtens O, Schoemaker RC, Lentjes EGWM, Romijn FPHTM, Cohen AF & van Meurs JC (2000), Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose, Ophthalmology: Journal of The American Academy of Ophthalmology 107(10).
- Editor in Chief
- Wetenschappelijke adviesraad